R-Pharm Arranged Joint Business Breakfast Meeting
OREANDA-NEWS. November 19, 2012. R-Pharm Group supported by the Agency of Strategic Initiatives (ASI), All-Russia Business Association “Delovaya Rossiay”, the Association of International Pharmaceutical Manufacturers (AIPM), the Association of International Pharmaceutical Manufacturers (AIPM) arranged the joint Business Breakfast meeting. Among the event speakers were Boris Titov Commissioner for the President on protection of entrepreneurs’ rights, Chairman of the Board of Founders All-Russia Business Association “Delovaya Rossiay”, Sergey Tsyb Director of the Department for Chemical and Engineering Complex and Bioengineering Technologies of Ministry of Industry and Trade (MIT), Timophey Nizhegorodtsev, Head of Department for Social Area and Trading Control of Federal Anti-Monopoly Service of the Russian Federation, G. Steven Burrill, President of Burrill & Company, and the directors of the world’s leading pharmaceutical companies. The participants of businesss breakfast meeting discussed the challenges of practical application of innovative medicines and forms of government and business cooperation aimed at the availability enhancement of high-efficient methods of treatment.
The moderator of the event which was held in friendly atmosphere was Alexey Repik, Chairman of the Board of R-Pharm Group, Co-Chairman on International Affairs of All-Russia Business Association “Delovaya Rossiya” (“Business Russia”). Alexey Repik raised the questions and challenges that appear at different stages of life cycle of innovations in pharmaceutical industry: from development to production, from clinical trials, registration to health care sphere and from specialist to patient. The participants of business meeting discussed as well the current challenges and stimulating measures to encourage the further development of pharmaceutical industry in Russia. The out-dated production capacities, the lack of highly-qualified specialists in pharmaceutical industry and effective finance facilities development are among key problems that should be resolved. The participants admitted that the development of innovative treatment methods and acceleration of implementation of high-performance developments into practical healthcare is the necessary condition of enhancement of healthcare efficiency in terms of fight with socially significant diseases. The particular attention was paid to the necessity of open communications between the pharmaceutical industry and health authorities, as well as the support of educational programs developed for doctors.
V.A. Dmitriev, General Director of ARPM, highlighted the need of changes in regulating system of drug circulation, in particular, the future establishment of a regulatory body, such as U.S. FDA, which could perform all the control and supervisory functions and create the sublegislative regulatory framework in terms of drug circulation as today these functions are divided between 5 separate institutions. However, V.A. Dmitriev believes, that at this stage the most crucial step should be done by the Ministry of Industry of the Russian Federation (Minprom) that should perform the imposed regulatory functions that should further stimulate the quickest industry conversion to GMP international standards, otherwise the innovative development is impossible. In addition, V.A. Dmitriev emphasized the importance of ethical promotion of innovations both in the period of clinical trials and product launch on the market.
At the end of Breakfast meeting V.G. Shipkov, Chief Executive Officer of the Association of International Pharmaceutical Manufacturers, said: “Today the innovations in the field of pharmacy have do not boundaries: the international team of medical developers is usually involved in development of structure of new medicinal products and examination of pharmacological and physicochemical features. The clinical trials are held in different countries, and in case of success this work will result in the development of an innovative medicine available for its implementation into therapeutic practices of different countries.” He added: “I believe that only through the international co-operation of all the parties concerned, i.e. the government, the society and the pharmaceutical industry, we can secure the favorable conditions for development and implementation of modern medicinal products for the benefit of the population of the Russian Federation.”
Комментарии